WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates (ADC), announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in AbTis’ portfolio of ADC products.
Under the partnership, AbTis will have access to WuXi XDC’s integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation and drug product manufacturing process development, as well as drug substance and drug product manufacturing. This full range of development and manufacturing services will be provided by WuXi XDC at facilities that are all located within a two-hour drive of each other.
“We are glad to be collaborating with WuXi XDC,” said Dr. Sang Jeon Chung, CEO of AbTis. “This partnership will allow us to leverage WuXi XDC’s world-class expertise in both innovative conjugation technologies and comprehensive capabilities for ADC development and manufacturing. We look forward to making more ADC products accessible to patients.”
“With our integrated services and know-how, we are pleased to be enabling AbTis to develop and manufacture its portfolio of ADC products,” said Dr. Jimmy Li, CEO of WuXi XDC. “This strategic partnership demonstrates the trust and confidence our clients have in our end-to-end services, maintained even during the COVID-19 lockdown period, when WuXi XDC teams showcased the strong execution and reflected our commitment to a culture of ‘Putting the Customer First.’ We will continue to accelerate and transform the discovery, development and manufacturing of bioconjugates, enabling our global partners and benefiting patients worldwide.”